REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX), a leader in gene therapy, announced its participation in two September investor conferences. The events will be held virtually, starting with Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020, followed by the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020, including a fireside chat at 8:45 a.m. ET. Interested investors can access a live webcast on REGENXBIO's website, with a replay available for 30 days post-event.

News Market Reaction – RGNX

-3.68%

-3.68% Session move

In the trading session that priced this news, RGNX declined 3.68%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Sept. 2, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV^® Technology Platform, today announced it will participate in the following September investor conferences, which will each be held in a virtual meeting format:

Citi's 15^th Annual BioPharma Virtual Conference
Date: Wednesday, September 9, 2020

Morgan Stanley 18^th Annual Global Healthcare Conference
Date: Tuesday, September 15, 2020
Fireside Chat: Tuesday, September 15, 2020 at 8:45 a.m. ET

A live webcast of the Morgan Stanley fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the fireside chat webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709

Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301123281.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO participate in the Citi's 15th Annual BioPharma Virtual Conference?

REGENXBIO will participate in Citi's 15th Annual BioPharma Virtual Conference on September 9, 2020.

What is the date of the Morgan Stanley 18th Annual Global Healthcare Conference for REGENXBIO?

REGENXBIO will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on September 15, 2020.

What time is REGENXBIO's fireside chat during the Morgan Stanley conference?

The fireside chat will take place at 8:45 a.m. ET on September 15, 2020.

How can investors access the live webcast of REGENXBIO's fireside chat?

Investors can access the live webcast on REGENXBIO's website in the Investors section.

Will there be a replay available for REGENXBIO's fireside chat?

Yes, a replay of the fireside chat will be available on REGENXBIO's website for approximately 30 days after the presentation.